Legend Biotech to Present Preliminary Phase 1 LB2102 Data and New CARVYKTI Analyses at ASCO 2026

On May 21, 2026, Legend Biotech Corporation announced it will present new clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. A key highlight includes a rapid oral presentation of preliminary Phase 1 data for LB2102, an investigational DLL3-targeted CAR-T therapy for relapsed or refractory small-cell lung cancer (SCLC) and large-cell neuroendocrine carcinoma (LCNEC). LB2102 is being developed under a global license agreement with Novartis. Additionally, the company will present new data for CARVYKTI (ciltacabtagene autoleucel), including a cytogenetic subgroup analysis from the Phase 3 CARTITUDE-4 study focusing on patients who responded to bridging therapy. Another poster will address the incidence of immune effector cell-associated enterocolitis (IEC-EC) across clinical trials. Legend Biotech will also host an investor webcast on May 31, 2026, featuring clinical experts to discuss CARVYKTI's impact on the multiple myeloma treatment landscape. CARVYKTI is currently the first BCMA-targeted CAR-T therapy approved for multiple myeloma patients with at least one prior line of therapy.